Skip to main content
SpringerLink
Log in

Entecavir: a guide to its use in chronic hepatitis B

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 2006; 66(12): 1605–22

    Article  PubMed  CAS  Google Scholar 

  2. Baraclude™ (entecavir): US prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2007 Feb

  3. European Medicines Agency (EMEA). Baraclude (entecavir): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Apr 5]

  4. Bifano M, Yan JH, Xie J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir [abstract no. 1149]. Hepatology 2004 Oct; 40(4 Suppl. 1): 663

    Google Scholar 

  5. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1001–10

    Article  PubMed  CAS  Google Scholar 

  6. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1011–20

    Article  PubMed  CAS  Google Scholar 

  7. Yao G, Chen C, Lu W, et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients [abstract no. 519 plus poster]. 41st Annual Meeting of the European Association for the Study of the Liver; 2006 Apr 26–30; Vienna

  8. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 Jun; 130(7): 2039–49

    Article  PubMed  CAS  Google Scholar 

  9. de Man RA, Mutimer D, Gish RG, et al. Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022) [abstract no. P090]. J Clin Virol 2006 Jul; 36Suppl. 2: S89.

    Article  Google Scholar 

  10. Poordad F, Dieterich DT, Min AD, et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (STUDY ETV-027) [abstract no. T1851]. Gastroenterology 2006; 130(4 Suppl. 2): 848

    Google Scholar 

  11. Sherman M, Martin P, Lee WM, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) [abstract no. 478]. Gastroenterology 2006 Apr; 130(4 Suppl. 2): 765

    Google Scholar 

  12. Sollano J, Schiff E, Carrilho F, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naive and lamivudine-refractory patients [abstract no. 1153]. Hepatology 2004 Oct; 40(4 Suppl. 1): 665A

    Google Scholar 

  13. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 2005 update. Liver Int 2005 Jun; 25: 472–89

    Article  PubMed  Google Scholar 

  14. Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006 Aug; 4(8): 936–62

    Article  PubMed  CAS  Google Scholar 

  15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34(6): 1225–41

    Article  PubMed  CAS  Google Scholar 

  16. Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19(1): 25–37

    Article  PubMed  CAS  Google Scholar 

  17. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682–95

    Article  PubMed  CAS  Google Scholar 

  18. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004 Apr; 39(3): 857–61

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Entecavir: a guide to its use in chronic hepatitis B. Drugs Ther. Perspect 23, 1–4 (2007). https://doi.org/10.2165/00042310-200723060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723060-00001

Search

Navigation